A new benchmark dataset for functional data analysis (FDA) is presented, focusing on the reconstruction of eye movements from EEG data. The contribution is twofold: first, open challenges and evaluation metrics tailored to FDA applications are proposed. Second, functional neural networks are used to establish baseline results for the primary regression task of reconstructing eye movements from EEG signals. Baseline results are reported for the new dataset, based on consumer-grade hardware, and the EEGEyeNet dataset, based on research-grade hardware.

Leveraging large language models (LLMs) to generate high-stakes documents, such as informed consent forms (ICFs), remains a significant challenge due to the extreme need for regulatory compliance and factual accuracy. Here, we present InformGen, an LLM-driven copilot for accurate and compliant ICF drafting by optimized knowledge document parsing and content generation, with humans in the loop. We further construct a benchmark dataset comprising protocols and ICFs from 900 clinical trials. Experimental results demonstrate that InformGen achieves near 100% compliance with 18 core regulatory rules derived from FDA guidelines, outperforming a vanilla GPT-4o model by up to 30%. Additionally, a user study with five annotators shows that InformGen, when integrated with manual intervention, attains over 90% factual accuracy, significantly surpassing the vanilla GPT-4o model's 57%-82%. Crucially, InformGen ensures traceability by providing inline citations to source protocols, enabling easy verification and maintaining the highest standards of factual integrity.

Accurately predicting drug-drug interactions (DDIs) is crucial for pharmaceutical research and clinical safety. Recent deep learning models often suffer from high computational costs and limited generalization across datasets. In this study, we investigate a simpler yet effective approach using molecular representations such as Morgan fingerprints (MFPS), graph-based embeddings from graph convolutional networks (GCNs), and transformer-derived embeddings from MoLFormer integrated into a straightforward neural network. We benchmark our implementation on DrugBank DDI splits and a drug-drug affinity (DDA) dataset from the Food and Drug Administration. MFPS along with MoLFormer and GCN representations achieve competitive performance across tasks, even in the more challenging leak-proof split, highlighting the sufficiency of simple molecular representations. Moreover, we are able to identify key molecular motifs and structural patterns relevant to drug interactions via gradient-based analyses using the representations under study. Despite these results, dataset limitations such as insufficient chemical diversity, limited dataset size, and inconsistent labeling impact robust evaluation and challenge the need for more complex approaches. Our work provides a meaningful baseline and emphasizes the need for better dataset curation and progressive complexity scaling.

Reliable drug safety reference databases are essential for pharmacovigilance, yet existing resources like SIDER are outdated and static. We introduce PVLens, an automated system that extracts labeled safety information from FDA Structured Product Labels (SPLs) and maps terms to MedDRA. In validation against 97 drug labels, PVLens achieved an F1 score of 0.882, with high recall (0.983) and moderate precision (0.799). By offering a scalable, more accurate and continuously updated alternative to SIDER, PVLens enhances real-time pharamcovigilance with improved accuracy and contemporaneous insights. Keywords: Pharmacovigilance, Natural Language Processing (NLP), Drug Safety, ADR 1 Introduction A clear understanding of known adverse effects, along with continuous surveillance for emerging safety concerns, is essential for patients, healthcare professionals, and pharmacovigilance (PV) scientists.

High Content Screening (HCS) microscopy datasets have transformed the ability to profile cellular responses to genetic and chemical perturbations, enabling cell-based inference of drug-target interactions (DTI). However, the adoption of representation learning methods for HCS data has been hindered by the lack of accessible datasets and robust benchmarks. To address this gap, we present RxRx3-core, a curated and compressed subset of the RxRx3 dataset, and an associated DTI benchmarking task. At just 18GB, RxRx3-core significantly reduces the size barrier associated with large-scale HCS datasets while preserving critical data necessary for benchmarking representation learning models against a zero-shot DTI prediction task. RxRx3-core includes 222,601 microscopy images spanning 736 CRISPR knockouts and 1,674 compounds at 8 concentrations. RxRx3-core is available on HuggingFace and Polaris, along with pre-trained embeddings and benchmarking code, ensuring accessibility for the research community. By providing a compact dataset and robust benchmarks, we aim to accelerate innovation in representation learning methods for HCS data and support the discovery of novel biological insights.

Despite decades of advancements in automated ligand screening, large-scale drug discovery remains resource-intensive and requires post-processing hit selection, a step where chemists manually select a few promising molecules based on their chemical intuition. This creates a major bottleneck in the virtual screening process for drug discovery, demanding experts to repeatedly balance complex trade-offs among drug properties across a vast pool of candidates. To improve the efficiency and reliability of this process, we propose a novel human-centered framework named CheapVS that allows chemists to guide the ligand selection process by providing preferences regarding the trade-offs between drug properties via pairwise comparison. Our framework combines preferential multi-objective Bayesian optimization with a docking model for measuring binding affinity to capture human chemical intuition for improving hit identification. Specifically, on a library of 100K chemical candidates targeting EGFR and DRD2, CheapVS outperforms state-of-the-art screening methods in identifying drugs within a limited computational budget. Notably, our method can recover up to 16/37 EGFR and 37/58 DRD2 known drugs while screening only 6% of the library, showcasing its potential to significantly advance drug discovery.

Is robotics about to have its own ChatGPT moment? Researchers are using generative AI and other techniques to teach robots new skills--including tasks they could perform in homes. Studies have indicated that psychedelic drugs, such as psilocybin and MDMA, have swift-acting and enduring antidepressant effects. Though the US Food and Drug Administration denied the first application for medical treatments involving psychedelics (an MDMA-based therapy) last August, these drugs appear to be on the road to mainstream medicine. Research into psilocybin has been slowed in part by the complexity of the trials, but the data already shows promise for the psychedelic compound within so-called magic mushrooms.

Causal abstraction techniques such as Interchange Intervention Training (IIT) have been proposed to infuse neural network with expert knowledge encoded in causal models, but their application to real-world problems remains limited. This article explores the application of IIT in predicting blood glucose levels in Type 1 Diabetes Mellitus (T1DM) patients. The study utilizes an acyclic version of the simglucose simulator approved by the FDA to train a Multi-Layer Perceptron (MLP) model, employing IIT to impose causal relationships. Results show that the model trained with IIT effectively abstracted the causal structure and outperformed the standard one in terms of predictive performance across different prediction horizons (PHs) post-meal. Furthermore, the breakdown of the counterfactual loss can be leveraged to explain which part of the causal mechanisms are more or less effectively captured by the model. These preliminary results suggest the potential of IIT in enhancing predictive models in healthcare by effectively complying with expert knowledge.

Precision therapeutics require multimodal adaptive models that generate personalized treatment recommendations. We introduce TxAgent, an AI agent that leverages multi-step reasoning and real-time biomedical knowledge retrieval across a toolbox of 211 tools to analyze drug interactions, contraindications, and patient-specific treatment strategies. TxAgent evaluates how drugs interact at molecular, pharmacokinetic, and clinical levels, identifies contraindications based on patient comorbidities and concurrent medications, and tailors treatment strategies to individual patient characteristics. It retrieves and synthesizes evidence from multiple biomedical sources, assesses interactions between drugs and patient conditions, and refines treatment recommendations through iterative reasoning. It selects tools based on task objectives and executes structured function calls to solve therapeutic tasks that require clinical reasoning and cross-source validation. The ToolUniverse consolidates 211 tools from trusted sources, including all US FDA-approved drugs since 1939 and validated clinical insights from Open Targets. TxAgent outperforms leading LLMs, tool-use models, and reasoning agents across five new benchmarks: DrugPC, BrandPC, GenericPC, TreatmentPC, and DescriptionPC, covering 3,168 drug reasoning tasks and 456 personalized treatment scenarios. It achieves 92.1% accuracy in open-ended drug reasoning tasks, surpassing GPT-4o and outperforming DeepSeek-R1 (671B) in structured multi-step reasoning. TxAgent generalizes across drug name variants and descriptions. By integrating multi-step inference, real-time knowledge grounding, and tool-assisted decision-making, TxAgent ensures that treatment recommendations align with established clinical guidelines and real-world evidence, reducing the risk of adverse events and improving therapeutic decision-making.

There is an increasing imperative to anticipate and understand the performance and safety of generative AI systems in real-world deployment contexts. However, the current evaluation ecosystem is insufficient: commonly used static benchmarks face validity challenges, and ad hoc case-by-case approaches rarely scale. In this piece, we advocate for maturing an evaluation science for generative AI systems. While generative AI creates unique challenges for system safety engineering and measurement science, the field can draw valuable insights from the development of safety evaluation practices in other fields including transportation, aerospace, and pharmaceutical engineering. In particular, we present three key lessons: evaluation metrics must be applicable to real-world performance, metrics must be iteratively refined, and evaluation institutions and norms must be established. Applying these insights, we outline a concrete path toward a more rigorous approach for evaluating generative AI systems.